

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sincere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO LICENSE AGREEMENT WITH NEXTCURE IN RELATION TO ADCs

This announcement is made by Sincere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on June 16, 2025, a subsidiary of the Company, Hainan Sincere Zaiming Pharmaceutical Co., Ltd. (海南先聲再明醫藥股份有限公司) (“**Sincere Zaiming**”), entered into a license agreement (the “**License Agreement**”) with NextCure, Inc. (Nasdaq: NXTC) (“**NextCure**”). Pursuant to the License Agreement, (i) NextCure obtains global rights (excluding the Greater China territory) to SIM0505, a novel antibody-drug conjugate (“**ADC**”) targeting CDH6 for the treatment of solid tumors; (ii) NextCure is eligible to access Sincere Zaiming’s proprietary TOPO isomerase 1 inhibitor (“**TOPOi**”) payload for a NextCure novel target ADC in preclinical development; and (iii) Sincere Zaiming will have Greater China rights to the novel target ADC.

Pursuant to the License Agreement, the Group is eligible to receive payments throughout the potential development phases, including upfront payment, development and sales milestones up to US\$745 million, as well as tiered royalties up to double digits on net sales outside of the Greater China territory.

ABOUT SIM0505

SIM0505 is directed to CDH6 (cadherin-6 or K-cadherin), a promising anti-tumor target, using a unique binding epitope with increased tumor binding compared to competing candidates. SIM0505 also features Simcere Zaiming's proprietary TOPOi payload, designed for broad anti-tumor activity while offering high systemic clearance to enlarge the therapeutic window. Preclinical studies have demonstrated robust and anti-tumor activity across multiple solid tumor models and a promising safety profile in toxicology models. SIM0505 is currently in Phase 1 clinical testing in China and NextCure expects to begin clinical testing in the U.S. in the third quarter of 2025.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Company focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

ABOUT SIMCERE ZAIMING

Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of the Company, dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. Simcere Zaiming is determined to deliver potentially transformative treatment options to cancer patients worldwide through independent research and development, complemented by strategic collaborations with partners.

ABOUT NEXTCURE, INC.

NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates. NextCure focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, June 16, 2025

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.